SLFN11 and cancer: SLFN11 was discovered by bioinformatics analyses of cancer cell databases as a causal and dominant genomic determinant of response to widely used anticancer drugs, including topoisomerase I (camptothecin) /II inhibitors (etoposide), alkylating agents (cisplatin and carboplatin) and DNA synthesis inhibitors (gemcitabine)19.